Sign in
CompletedNo phase

Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Key facts

Who runs it
Wave Neuroscience
Where
Bellevue, Bryn Mawr, Columbus, Costa Mesa, Long Beach, Plano, Raleigh, and San Diego, United StatesSee the 8 sites
Trial code
Status
Completed
People taking part
158 people enrolled
Started
4 Apr 2022
Ended
4 Nov 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Active MeRT Treatment
  • Sham MeRT Treatment
Record updated
15 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Participants must meet all inclusion criteria to qualify for enrollment in the study:
  • Willing and able to consent to participate in the study
  • Age 18 - 65 years
  • Diagnosis of PTSD according to DSM-V criteria via CAPS-5
  • Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms persisting for a minimum of 6 months prior to the Screening Visit
  • Minimum PCL-5 score of 30

Who cannot take part

  • Participation in any interventional research protocol within 3 months prior to the Screening Visit
  • Treated within 30 days of the Screening Visit with any antipsychotic medication
  • Treated within 30 days of the Screening Visit with any benzodiazepine or anticonvulsant medications
  • Current treatment with any restricted concomitant medication (i.e., NDRI, SSRI, SNRI, or QBDZ) that has not been stable for the preceding 60 days at the time of the Screening Visit
  • Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within the head, excluding the mouth, or on the head, that cannot be safely removed
  • History of open skull injury
  • History of a neurological disorder including, but not limited to:; Seizure disorder; Any condition likely to be associated with increased intracranial pressure; Space occupying brain lesion
  • History of cerebrovascular accident
  • History of cerebral aneurysm
  • EEG abnormalities that indicate risk of seizure, i.e., abnormal focal or general slowing, or ictal spikes, during the EEG recording
  • History of any type of ECT, rTMS, or MeRT treatment
  • Biomedical devices, including those not in or on the head, that are either implanted or not safe to remove, that may be affected by the magnetic field of the stimulator (e.g., cardiac pacemaker, cardioverter defibrillator (ICD), or medication dispensing device)
  • Clinically significant medical illness or condition, including, but not limited to, any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunction, or chronic excessive alcohol consumption, that in the Investigator's judgment might pose a potential safety risk to the participant or limit the interpretation of trial results
  • Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures, or any condition, including inability to communicate in English, which in the judgment of the Investigator might prevent the participant from completing the study, render study results uninterpretable, or represent an unacceptable safety risk to the participant or study personnel that is not otherwise listed in exclusion criteria
  • Clinically significant psychopathology, including, but not limited to, schizophrenia or bipolar disorder, or other psychiatric disorder that in the Investigator's judgment might pose a potential safety risk to the participant, or limit the interpretation of trial results
  • Index trauma occurred before the age of 16 years
  • Participants will be excluded from study participation if one or more of the following exclusion criteria apply:
  • Inability to calculate the EEG intrinsic alpha frequency at Screening
  • Pregnant, or female unwilling to use effective birth control during the course of the trial
  • Plan to move away from the area, or knowledge that there will be an absence from the area, within 80 days following the Screening Visit (inclusive)
  • An elevated risk of suicide or violence to others
  • Current psychotherapeutic treatment, expected to continue throughout the trial, that was begun in the preceding 60 days at the time of the Screening Visit

Where in United States

  • Seattle Neuropsychiatric Treatment Center (Seattle NTC)Bellevue, United States
  • Center for Interventional Pain and SpineBryn Mawr, United States
  • Columbus Brain Research CenterColumbus, United States
  • BrainHealth SolutionsCosta Mesa, United States
  • VA Long Beach Healthcare SystemLong Beach, United States
  • Texas A&M Research CenterPlano, United States
  • UNC- Rex HospitalRaleigh, United States
  • SoCal Neuroscience Research UnitSan Diego, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and efficacy of individualized, Biometrics-guided Magnetic e-Resonance Therapy (MeRT) treatment of Post-Traumatic Stress Disorder

The 2 groups in the trial

  • Active MeRT TreatmentExisting treatment, for comparison

    Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.

  • Sham MeRT TreatmentSham treatment, for comparison

    Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Double Blind, Randomized, Sham-Controlled, Clinical Trial to Evaluate The Safety And Efficacy Of Biometrics-Guided Magnetic EEG Resonance Therapy (MeRT) Treatment Of Post-Traumatic Stress Disorder
Record updated
15 January 2026